Integrating stereotactic body radiation therapy in stage II/III non-small cell lung cancer: is local control important?

References

• American Cancer Society. Cancer facts and figure. American Cancer Society; Atlanta, GE, USA: 2006
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell. Lung Cancer. NCCN Guidelines Version 3.2014. National Comprehensive Cancer Network; USA: 2014
   Google Scholar
• Keller SM, Adak S, Wagner H, et al. Mediastinal lymph node dissection improves survival in patients with stage II and IIIa non-small cell lung cancer. Ann Thorac Surg 2000;70:358-66
   PubMedGoogle Scholar
• Dillman RO, Herndon J, Seagren S, et al. Improved survival in stage III non-small cell lung cancer: seven year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-15
   PubMed Web of Science ®Google Scholar
• Sause W, Kolesar P, Taylor SIV, et al. Final results of a phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest 2000;117(2):358-64
   PubMed Web of Science ®Google Scholar
• Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Rad Oncol Biol Phys 2005;61(2):318-28
   PubMedGoogle Scholar
• Bradley J, Paulus R, Komaki R, et al. A Randomised Phase III comparison of standard dose (60Gy) vs high dose (74Gy) conformal chemo-radiotherapy ±cetuximab in stage IIIA/B NSCLC: preliminary findings on radiation dose in RTOG 0617. In: Proceeding of ASTRO; Miami, FL, USA; 2011
   Google Scholar
• Bradley J, Moughan J, Graham MV, et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small cell lung cancer: RTOG 0117. Int J Rad Oncol Biol Phys 2010;77(2):367-72
   PubMedGoogle Scholar
• Bradley J. A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group. Semin Oncol 2005;32(2 Suppl 3):S111-13
   Google Scholar
• Martel M, Ten Haken R, Hazuka M, et al. Estimation of tumor control probability from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999;24:31-7
   PubMed Web of Science ®Google Scholar
• Ohnishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT)) for stage I non-small-cell lung cancer: updated results of 257 patients in a Japanese Multi-institutional study. J Thorac Oncol 2007;2(7 Suppl 3):S94-100
   Google Scholar
• Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74Gy) in stage III non-small cell lung cancer: CALGB 30105. J Clin Oncol 2008;26(15):2457-63
   PubMedGoogle Scholar
• Lee CB, Stinchcombe TE, Hoore DT, et al. Late complications of high-dose (>/=66Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non – small cell lung cancer. J Thorac Oncol 2009;4(1):74-9
   PubMed Web of Science ®Google Scholar
• Willner J, Baier K, Caragiani E, et al. Dose, volume and tumorcontrol redictions in primary radiotherapy of non-small cell lung cancer. Int J Rad Oncol Biol Phys 2002;52:382-9
   PubMed Web of Science ®Google Scholar
• Curran WJ, Paulus R, Langer CJ, et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III Trial RTOG 9410. J Natl Cancer Inst 2011;103:1452-60
   PubMedGoogle Scholar
• McGarry RC, Song G, Des Rosiers P, Timmerman R. Observation-only management of early stage medically inoperable lung cancer: poor outcome. Chest 2002;121:1155-8
   PubMed Web of Science ®Google Scholar
• Sibley GS. Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma. Cancer 1998;82:433-8
   PubMed Web of Science ®Google Scholar
• Timmerman R, Papiez L, McGarry R. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer patients. Chest 2003;124:1946-55
   PubMed Web of Science ®Google Scholar
• McGarry RC, Papiez L, Williams M, et al. Stereotactic body radiation therapy of early stage non-small cell lung carcinoma: phase I study. Int J Rad Oncol Biol Phys 2005;63:1010-15
   PubMed Web of Science ®Google Scholar
• Hiraoka M, Nagata Y. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer. Int J Clin Oncol 2004;9:352-5
   PubMedGoogle Scholar
• Mehta N, King CR, Agazarayan N, et al. Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: a pooled analysis of biological equivalent dose and local control. Pract Radiat Oncol 2012;2:288-95
   PubMedGoogle Scholar
• Hepel JT, Peter J, Hiatt JR, et al. Dosimetric feasibility of dose escalation using sbrt boost for stage III non-small cell lung cancer. Front Oncol 2012;2:124
   PubMedGoogle Scholar
• Karam SD, Horne ZD, Hong RL, et al. Dose escalation with stereotactic body radiation therapy boost for locally advanced non-small cell lung cancer. Radiat Oncol 2013;8:179
   PubMed Web of Science ®Google Scholar
• Feddock J, Arnold S M, Shelton BJ, et al. Stereotactic body radiotherapy (SBRT) can be used safely to boost residual disease in locally advanced non-small cell lung cancer (NSCLC): a prospective study. Int J Radiat Oncol Biol Phys 2013;85(5):1325-31
   PubMedGoogle Scholar
• Feddock J, Arnold SM, Shelton BJ, et al. Risk for fatal pulmonary hemorrhage does not appear to be increased following dose escalation using stereotactic body radiotherapy (SBRT) in locally advanced non-small cell lung cancer (NSCLC). J Radiosurg Stereo Body Radiat Ther 2013;2(3):235-42
   Google Scholar
• Senan S, Burgers S, Samson MJ, et al. Can elective nodal irradiation be omitted in Stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys 2002;54(4):999-1006
   PubMedGoogle Scholar
• Fernandes AT, Mitra M, Xanthopoulos E, et al. The impact of extent and location of mediastinal lymph node involvement on survival in stage III non-small cell lung cancer patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2012;83(1):340-7
   PubMedGoogle Scholar
• Rosenzweig KE, Sim SE, Mychalczak B, et al. Elective nodal treatment in the management of non-small cell lung cancer with three dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:681-5
   PubMed Web of Science ®Google Scholar
• Sulman EP, Komaki R, Klopp AH, et al. Exclusion of elective nodal irradiation is associated with minimal elective nodal failur in non-small cell lung cancer. Radiat Oncol 2009;4:5-9
   PubMedGoogle Scholar
• Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;25(30):4833-9
   Google Scholar
• Panos RJ, Barr LF, Silverman HJ. Factors associated with fatal hemoptysis in cancer patients. Chest 1988;94(5):1008-13
   PubMedGoogle Scholar
• Sandomenico C, Costazo R, Carillio G, et al. Bevicizumab in NSCLC: development, current status and issues. Curr Med Chem 2012;19(7):961-7
   PubMedGoogle Scholar
• Kelly JF, Delclos ME, Morice RC, et al. High dose rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10 year MD Anderson cancer center experience. Int J Radiat Oncol Biol Phys 2000;48(3):697-702
   PubMedGoogle Scholar
• Barami K, Grow A, Brem S, et al. Vascular complications following radiosurgery for meningiomas. Neurosurg Focus 2007;22(3):E9
   Google Scholar
• Fajardo LF, Berthrong M. Vascular lesions following radiation. Pathol Ann 1998;23:297-330
   Google Scholar
• Kamiryo T, Lopes MB, Kasell NF, et al. Radiosurgery-induced microvascular alterations preceded necrosis of the brain neutrophil. Neurosurgery 2001;49:409-14
   PubMedGoogle Scholar
• Phernambucq EC, Hartemink EJ, Smith EF, et al. Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes. J Thorac Oncol 2012;7:1271-5
   PubMedGoogle Scholar
• Tinnel B, Mendonca MS, Henderson M, et al. Pulmonary hilar stereotactic body radiation therapy in the rat. Technol Cancer Res Treat 2007;6(5):425-31
   PubMedGoogle Scholar
• Pan H, Rose BS, Simpson DR, et al. Clinical pratice patterns of lung stereotactic body radiation therapy in the United States: a secondary analysis. Am J Clin Oncol 2013;36:269-72
   PubMedGoogle Scholar
• Annema JT, van Meerbeeck JP, Rintoul RC. Mediastinoscopy vs. endosonography for mediastinal nodal staging in lung cancer. A randomised trial. JAMA 2012;304(20):2245-52
   Google Scholar
• Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995;36:1836-9
   PubMed Web of Science ®Google Scholar
• Visser EP, Boerman OC, Oyen WJ. SUV: from silly useless value to smart uptake value. J Nucl Med 2010;51:173-5
   PubMedGoogle Scholar
• Adams MC, Turkington T, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. Am J Roentgenol 2010;195:310-20
   PubMedGoogle Scholar
• Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-46
   PubMed Web of Science ®Google Scholar
• Bataini JP, Asselain B, Jaulerry C, et al. A multivariate primary tumor control analysis in 465 patients treated by radical radiotherapy for cancer of the tonsillar region: clinical and treatment parameters as prognostic factors. Radiother Oncol 1998;14:265-7
   Google Scholar
• Lanciano RM, Pajak TF, Martz K, et al. The influence of treatment time o outcome for squamous cell cancer of the uterine cervix treated with radiation: a Patterns of Care Study. Int J Radiat Oncol Biol Phys 1993;25:329-34
   PubMedGoogle Scholar
• Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomized multicentre trial. CHART Steering Committee. Lancet 1997;350:161-5
   PubMed Web of Science ®Google Scholar
• Hatton M, Nankivell M, Lyn E. Induction chemotherapy and continuous hyperfractionated accelerated radiotherapy (CHART) for patients with locally advanced inoperable non–small-cell lung cancer: the MRC INCH randomized trial. Int J Radiat Oncol Biol Phys 2011;81(3):712-18
   PubMed Web of Science ®Google Scholar